Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2005 Dec 1;15(23):5340-3. Epub 2005 Sep 26.

Rapamycin analogs with reduced systemic exposure.

Author information

1
Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA. rolf.wagner@abbott.com

Abstract

The synthesis and biological activities of rapamycin (I) analogs modified at the C-40 position are reported. Emphasis placed on compounds that potentially have an improved safety profile on account of their shorter in vivo half-life when compared with rapamycin.

PMID:
16185865
DOI:
10.1016/j.bmcl.2005.06.106
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center